{"article_title": "Google vs. Samsung: The Ultimate Biotech Showdown -- The Motley Fool", "article_keywords": ["fool", "biotech", "google", "worldthats", "billion", "samsung", "motley", "showdown", "investing", "vs", "health", "ultimate", "williamson", "worth", "market", "care"], "article_url": "http://www.fool.com/investing/general/2014/05/17/google-vs-samsung-the-ultimate-biotech-showdown.aspx", "article_text": "\"Our mandate is to become No. 1 in everything we enter into, so our long-term goal is to become a leading pharmaceutical company in the world.\"\n\nThat's what Christopher Hansung Ko, CEO of Samsung's (NASDAQOTH:SSNLF) Bioepis unit, had to say about his company's unexpected dive into biotech.\n\nOf course, to become that dominant, Samsung would have to beat a lot of other pharma companies -- and face off against Google (NASDAQ:GOOGL) (NASDAQ:GOOG), whose investments in Calico to combat aging also have transformative possibilities.\n\nThe Korean conglomerate is looking to compete in biosimilars, or the generic versions of biologic drugs, and it's paired up with a number of health care heavyweights (including Biogen) to make that happen. It's a pretty target-rich environment, and a market that may be worth as much as $24 billion by 2019. Samsung isn't idly grabbing headlines either -- it's investing $2 billion to get this foray started, with the expectation of selling $1.8 billion a year in biopharmaceutical products by 2020.\n\nIn the following video, from Market Checkup, the Motley Fool's health care-focused investing show, Motley Fool health care analysts Michael Douglass and David Williamson dig into the details and look at the investing takeaways in this surprising and exciting story.", "article_metadata": {"publish_time": "12:00", "date": "2014-05-17T16:00:00Z", "description": "These two tech companies are getting involved in a pretty surprising area.", "ResponsiveALP": "1Ses_2things-v-single_single-control_50", "author": "Michael Douglass and Dave Williamson", "promo": "These two tech companies are getting involved in a pretty surprising area.", "twitter": {"site": "@themotleyfool", "description": "These two tech companies are getting involved in a pretty surprising area.", "title": "Google vs. Samsung: The Ultimate Biotech Showdown --  The Motley Fool"}, "og": {"site_name": "The Motley Fool", "description": "These two tech companies are getting involved in a pretty surprising area.", "title": "Google vs. Samsung: The Ultimate Biotech Showdown --  The Motley Fool", "url": "http://www.fool.com/investing/general/2014/05/17/google-vs-samsung-the-ultimate-biotech-showdown.aspx", "image": "https://g.foolcdn.com/image/?url=http%3A%2F%2Fg.foolcdn.com%2Fassets%2Fimages%2Ffool%2Ftmf-logo.png&h=630&w=1200&op=resize", "type": "article"}, "headline": "Google vs. Samsung: The Ultimate Biotech Showdown", "fb": {"admins": 50808187550, "page_id": 7240312795, "app_id": 50808187550}, "bureau": "usmf-health-care", "STORY_UID": "791174d2-dd48-11e3-a749-0050569d4be0", "pitch": 681, "msvalidate.01": "8D40D58712924715BAA79D135A6C8DDA", "gsa_date": "2014 05 17", "tickers": "GOOGL,SSNLF,GOOG", "viewport": "width=device-width, initial-scale=1.0, maximum-scale=1.0"}, "article_summary": "In the following video, from Market Checkup, the Motley Fool's health care-focused investing show, Motley Fool health care analysts Michael Douglass and David Williamson dig into the details and look at the investing takeaways in this surprising and exciting story.\nThe Korean conglomerate is looking to compete in biosimilars, or the generic versions of biologic drugs, and it's paired up with a number of health care heavyweights (including Biogen) to make that happen.\nThat's what Christopher Hansung Ko, CEO of Samsung's (NASDAQOTH:SSNLF) Bioepis unit, had to say about his company's unexpected dive into biotech.\nIt's a pretty target-rich environment, and a market that may be worth as much as $24 billion by 2019.\n1 in everything we enter into, so our long-term goal is to become a leading pharmaceutical company in the world.\""}